InVitae (NVTA) – PRNewswire
-
Invitae Publishes its Environmental, Social and Governance (ESG) Report
-
Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance
-
Invitae Launches Update to Invitae Generation™: Clinical Variant Modeling Improves Variant Classification
-
Invitae Reports Estimated Unaudited Fourth Quarter and Full Year 2023 Financial Results
-
Invitae to Present Data at the 2024 ACMG Annual Clinical Genetics Meeting
-
Invitae Files for Voluntary Chapter 11 Protection; Pursues Sale Process
-
Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics
-
Invitae Completes Sale of Reproductive Health Assets to Natera
-
Invitae Divests Ciitizen Health Data Platform and Implements Further Cost Cuts
-
Invitae Reports Third Quarter 2023 Financial Results
-
Invitae Launches Enhanced Chemistry of MRD Test to Better Serve Biopharmaceutical Clinical and Research Partnerships
-
Invitae to Announce Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
-
Landmark Study Reveals Magnitude of Uncertain Results in Clinical Genetic Testing for Hereditary Disease, Points to Evidence-Based Solutions to Reach Definitive Results
-
Invitae Appoints Dr. David Sholehvar as Chief Operating Officer
-
Rural Hospital System Demonstrates the Clinical Benefits of Implementing Universal Hereditary Cancer Testing in Patients with Breast Cancer
-
Invitae to Present Data at the National Society of Genetic Counselors 42nd Annual Conference That Supports Advancements in Medical Genomics
-
Invitae's Common Hereditary Cancers Panel Receives FDA Market Authorization
-
Invitae Announces Appointment of Finance Veteran Ana Schrank as CFO
-
Invitae Receives Notice of Non-Compliance with NYSE Minimum Share Price Continued Listing Standard
-
Invitae Hires Industry Veteran Robert Guigley as Chief Commercial Officer
-
Clinical Trial Results Support Genetic Testing of All Patients with Prostate Cancer
-
Invitae Announces Selection of Finance Executive Robert Dickey as Interim CFO
-
Invitae Reports Second Quarter 2023 Financial Results
-
Invitae to Announce Second Quarter 2023 Financial Results on Tuesday, August 8, 2023
-
Invitae to Present at the William Blair 43rd Annual Growth Stock Conference
-
New Research Insights to be Presented by Invitae at the 2023 ASCO Annual Meeting Reinforce the Critical Role of Germline Genetic Testing in Oncology
-
Invitae Announces CFO Transition and Selection of Veteran Finance Executive Christine Gorjanc as Interim CFO
-
Invitae to Appeal Trial Verdict
-
Invitae Reports First Quarter 2023 Financial Results
-
Invitae to Announce First Quarter 2023 Financial Results on Tuesday, May 9, 2023
-
Invitae Publishes Annual Environmental, Social and Governance (ESG) Report
-
New Study Findings Published in Nature Show Circulating Tumor DNA (ctDNA) Can Predict and Detect Cancer Recurrence Earlier In Non-Small Cell Lung Cancer
-
Invitae and Deerfield Management Partner to Create Novel Therapeutics for Rare Diseases
-
Invitae Announces Partnership with Epic to Streamline Genetic Testing
-
Invitae Appoints Dr. W. Michael Korn as Chief Medical Officer for Oncology
-
Invitae to Present Data at The American Clinical Genetics Meeting 2023 That Supports Removing Barriers to Genetic Testing
-
Invitae's PCM Assay for Minimal Residual Disease Receives its First Commercial Coverage
-
Invitae to Present at the TD Cowen 43rd Annual Health Care Conference
-
Invitae Announces Convertible Notes and Share Exchange and New Convertible Notes Issuance
-
Invitae Reports Fourth Quarter and Full Year 2022 Financial Results; Provides Company Updates
-
Invitae to Announce Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 28, 2023
-
Invitae Appoints William H. Osborne to its Board of Directors
-
Invitae Reports Preliminary 2022 Financial Results
-
Invitae to Present at the 41st Annual J.P. Morgan Healthcare Conference
-
Invitae Completes Selected Assets Sale of its Next Generation Sequencing (NGS) research assays to Integrated DNA Technologies, Inc.
-
Invitae Executive Appointed to National Health Information Technology Advisory Committee
-
Invitae Releases Data Use Transparency Report, Demonstrating the Impact of Patient Data on Genetic Research
-
Invitae Launches Rare Patient Network for Pediatric Patients With Rare Neurodevelopmental Diseases
-
Invitae Showcases Advances in Medical Genomics at the National Society of Genetic Counselors (NSGC) 41st Annual Conference
-
Invitae Reports Third Quarter 2022 Financial Results
Back to NVTA Stock Lookup
